Septic Shock
Conditions
Brief summary
Assessing the safety and efficacy of the adjunctive use of midodrine as a vasopressor in septic shock patients by measuring the difference in the mortality rates between control and intervention groups.
Interventions
Patients will receive standard treatment in accordance to surviving sepsis campaign guidelines plus oral midodrine 10 mg/ 8 hours till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours) or death.
Sponsors
Noha Mansour
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult aged 18 years or older diagnosed with septic shock. * Hypotensive and require IV vasopressor for more than 24 hours.
Exclusion criteria
* Hypovolemic shock. * Severe organic heart disease (ejection fraction \<30 percent). * Bradycardia (HR\<50 b/m). * Chronic kidney disease (serum creatinine \>2mg/dl). * Thyrotoxicosis. * Pheochromocytoma. * Known allergy to midodrine. * Unable to administer an oral medication.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality rates | Time Frame: Starting from date of randomization till shock reversal or date of death from any cause, whichever came first,assessed up to 30 days | The primary outcome is measuring the difference in ICU mortality rates between control and intervention group. |
Countries
Egypt
Outcome results
None listed